ResMed (NYSE:RMD) Price Target Raised to $270.00

ResMed (NYSE:RMD) had its price objective lifted by Wells Fargo & Company from $265.00 to $270.00 in a research report released on Friday morning,Benzinga reports. They currently have an equal weight rating on the medical equipment provider’s stock.

A number of other research analysts have also recently commented on RMD. Robert W. Baird set a $281.00 target price on shares of ResMed in a report on Friday. Piper Sandler increased their price objective on shares of ResMed from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Friday. KeyCorp reiterated an “overweight” rating and issued a $302.00 price target on shares of ResMed in a research note on Friday. Mizuho dropped their price objective on shares of ResMed from $310.00 to $300.00 and set an “outperform” rating for the company in a report on Friday, October 31st. Finally, Royal Bank Of Canada raised their target price on ResMed from $311.00 to $314.00 and gave the stock an “outperform” rating in a research report on Friday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. According to data from MarketBeat, ResMed has an average rating of “Moderate Buy” and a consensus price target of $297.91.

ResMed Trading Up 0.1%

Shares of RMD opened at $257.76 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.32 and a current ratio of 3.06. ResMed has a 52-week low of $199.92 and a 52-week high of $293.81. The firm has a market cap of $37.62 billion, a price-to-earnings ratio of 25.50, a PEG ratio of 1.72 and a beta of 0.87. The business’s fifty day moving average is $251.04 and its 200-day moving average is $263.37.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, January 29th. The medical equipment provider reported $2.81 earnings per share for the quarter, topping the consensus estimate of $2.68 by $0.13. ResMed had a return on equity of 25.20% and a net margin of 27.53%.The business had revenue of $1.42 billion during the quarter, compared to the consensus estimate of $1.40 billion. During the same period in the prior year, the company earned $2.43 EPS. ResMed’s revenue for the quarter was up 11.0% on a year-over-year basis. Equities analysts anticipate that ResMed will post 9.47 EPS for the current fiscal year.

ResMed Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 19th. Stockholders of record on Thursday, February 12th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date is Thursday, February 12th. ResMed’s payout ratio is presently 23.74%.

Insiders Place Their Bets

In other ResMed news, Director Witte Jan De sold 2,055 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $255.00, for a total value of $524,025.00. Following the transaction, the director directly owned 4,261 shares in the company, valued at $1,086,555. The trade was a 32.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $248.83, for a total value of $497,660.00. Following the completion of the sale, the director owned 66,773 shares in the company, valued at approximately $16,615,125.59. The trade was a 2.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 21,594 shares of company stock valued at $5,403,495. Insiders own 0.65% of the company’s stock.

Institutional Trading of ResMed

Several hedge funds and other institutional investors have recently modified their holdings of RMD. SJS Investment Consulting Inc. boosted its stake in ResMed by 1,433.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 86 shares during the period. Imprint Wealth LLC purchased a new stake in shares of ResMed in the third quarter worth $26,000. WFA of San Diego LLC bought a new stake in ResMed during the second quarter valued at $26,000. ORG Partners LLC grew its position in ResMed by 181.6% during the fourth quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 69 shares in the last quarter. Finally, Sunbelt Securities Inc. bought a new position in ResMed in the 3rd quarter worth about $31,000. Institutional investors own 54.98% of the company’s stock.

Key ResMed News

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q2 results beat consensus — GAAP diluted EPS of $2.68 (non‑GAAP $2.81) vs. Street estimates ~ $2.68, revenue $1.423B (+11% YoY), 320 bps gross‑margin improvement and $340M operating cash flow. These metrics support near‑term earnings credibility and cash generation. Read More.
• Positive Sentiment: Board declared a quarterly cash dividend of $0.60 per share (record Feb 12; payable Mar 19), signaling capital return commitment and supporting income investors. Read More.
• Positive Sentiment: Product/innovation catalysts: FDA cleared an AI‑enabled device (“Smart Comfort”) to personalize CPAP settings — strengthens digital/AI positioning and could boost adherence and recurring device/accessory demand. Read More.
• Positive Sentiment: Wells Fargo nudged its price target to $270 (from $265) with an “equal weight” rating — a modest analyst lift that implies limited near‑term upside from that shop. Read More.
• Neutral Sentiment: Analyst landscape remains mixed but generally favorable — several firms maintain outperform/buy views and available median targets sit materially above current price, leaving room for differing investor expectations. Read More.
• Neutral Sentiment: Company hosted the Q2 webcast and transcripts are posted — useful for hearing management’s guide/comments on demand, supply and margin outlook. Read More.
• Negative Sentiment: Expenses rose: SG&A and R&D both increased (~12% YoY) and the company recorded $6M in restructuring charges; higher operating costs could pressure margins if growth slows. Read More.
• Negative Sentiment: Notable insider selling activity was reported in recent months (multiple sales by senior executives), which some investors view as a modest governance/conviction caution. Read More.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.